PMID- 24379912
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20131231
LR  - 20211021
IS  - 1948-9358 (Print)
IS  - 1948-9358 (Electronic)
IS  - 1948-9358 (Linking)
VI  - 4
IP  - 6
DP  - 2013 Dec 15
TI  - Betatrophin: A liver-derived hormone for the pancreatic beta-cell proliferation.
PG  - 234-7
LID - 10.4239/wjd.v4.i6.234 [doi]
AB  - The pancreatic beta-cell failure which invariably accompanies insulin resistance in 
      the liver and skeletal muscle is a hallmark of type-2 diabetes mellitus (T2DM). 
      The persistent hyperglycemia of T2DM is often treated with anti-diabetic drugs 
      with or without subcutaneous insulin injections, neither of which mimic the 
      physiological glycemic control seen in individuals with fully functional 
      pancreas. A sought after goal for the treatment of T2DM has been to harness the 
      regenerative potential of pancreatic beta-cells that might obviate a need for 
      exogenous insulin injections. A new study towards attaining this aim was reported 
      by Yi et al, who have characterized a liver-derived protein, named betatrophin, 
      capable of inducing pancreatic beta-cell proliferation in mice. Using a variety of 
      in vitro and in vivo methods, Yi et al, have shown that betatrophin was expressed 
      mainly in the liver and adipose tissue of mice. Exogenous expression of 
      betatrophin in the liver led to dramatic increase in the pancreatic beta-cell mass 
      and higher output of insulin in mice that also concomitantly elicited improved 
      glucose tolerance. The authors discovered that betatrophin was also present in 
      the human plasma. Surprisingly, betatrophin has been previously described by 
      three other names, i.e., re-feeding-induced fat and liver protein, lipasin and 
      atypical angiopoeitin-like 8, by three independent laboratories, as nutritionally 
      regulated liver-enriched factors that control serum triglyceride levels and lipid 
      metabolism. Yi et al demonstration of betatrophin, as a circulating hormone that 
      regulates beta-cell proliferation, if successfully translated in the clinic, holds 
      the potential to change the course of current therapies for diabetes.
FAU - Raghow, Rajendra
AU  - Raghow R
AD  - Rajendra Raghow, Department of Veterans Affairs Medical Center, Memphis, TN 
      38104, United States.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Diabetes
JT  - World journal of diabetes
JID - 101547524
PMC - PMC3874481
OTO - NOTNLM
OT  - Insulin resistance
OT  - Liver-derived betatrophin
OT  - Pancreas beta-cell regeneration
OT  - Type 2 diabetes mellitus
EDAT- 2014/01/01 06:00
MHDA- 2014/01/01 06:01
PMCR- 2013/12/15
CRDT- 2014/01/01 06:00
PHST- 2013/08/02 00:00 [received]
PHST- 2013/09/02 00:00 [revised]
PHST- 2013/10/16 00:00 [accepted]
PHST- 2014/01/01 06:00 [entrez]
PHST- 2014/01/01 06:00 [pubmed]
PHST- 2014/01/01 06:01 [medline]
PHST- 2013/12/15 00:00 [pmc-release]
AID - 10.4239/wjd.v4.i6.234 [doi]
PST - ppublish
SO  - World J Diabetes. 2013 Dec 15;4(6):234-7. doi: 10.4239/wjd.v4.i6.234.